Rina-S for platinum-resistant ovarian cancer in China
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer confirmed by tissue biopsy
- Previously received 1 to 4 lines of cancer treatment, with cancer that has grown back after the most recent treatment
- Must have received platinum chemotherapy in the past; if bevacizumab was standard in your region, you should have received it (unless you couldn't tolerate it); if you have a BRCA gene mutation and responded well to platinum therapy, you should have received PARP inhibitor maintenance treatment
- Have 'platinum-resistant' disease, meaning cancer progressed 92–183 days after your first platinum therapy, or within 183 days if you've had multiple lines of platinum therapy
- No eye problems that would make you ineligible for mirvetuximab soravtansine (such as corneal transplant, uncontrolled glaucoma, wet macular degeneration, or vision in only one eye)
- No severe fluid buildup in the abdomen or around the lungs that requires draining more than every 4 weeks, and no bowel obstruction in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.